ADDMEDICA
ADDMEDICA has announced that the US Food and Drug Administration (FDA) has approved Siklos® (hydroxyurea tablets) in paediatric patients, two years of age and older, suffering from sickle cell anaemia.
Approval was obtained under a priority review and orphan drug designation.
Particularly suitable for paediatric populations, Siklos® offers dosing options to facilitate adjustment based on the patient’s weight to obtain the best efficacy/tolerance ratio for each child throughout the growth years.
FDA-approval of Siklos® was granted based on efficacy and safety data collected in a cohort study, Escort-HU, which included several hundred child and adult patients treated with Siklos® in Europe.
According to François Anger, President of ADDMEDICA:
“FDA-approval of Siklos® is a major breakthrough in the treatment of American children with sickle cell anaemia. European patients have been benefitting from Siklos® , the only form of hydroxyurea indicated in paediatric care in the world, since 2007. This successful outcome can also be attributed to the patients who agreed to participate in the Escort-HU study and the physicians who allowed it to happen. With the new FDA-approval, ADDMEDICA consolidates its leadership in the treatment of sickle cell anaemia by continuing to invest in the development and availability of this essential therapeutic product in new countries.”
Siklos® will be marketed in the United States by Medunik USA Inc.
“We’re pleased to partner with ADDMEDICA to distribute this orphan drug which is recognised as the reference drug treatment in sickle cell anaemia. It will improve the health and quality of life of hundreds of children with the disease in the United States,” said Éric Gervais, Executive Vice-President of Medunik. “The launch of Siklos® in the next few months establishes our footprint in the United States in orphan drug therapies and is the latest in a series of significant milestones for the company.”
About sickle cell anaemia
Sickle cell anaemia is a particularly disabling disease, whose most common acute manifestations are painful vaso-occlusive crises in the bones, lungs (acute chest syndrome) and most vascularised organs, and strokes. It may be life-threatening, especially in the case of acute chest syndrome.
The disease is caused by abnormal haemoglobin molecules causing red blood cells to become stiff and sickle-shaped under certain conditions whence the name of sickle-cell anaemia.
These sickled red blood cells tend to pile together, creating clots, and blocking the flow of blood through vessels and thus causing vaso-occlusive crises.
The disease is accompanied by varying degrees of anaemia and chronic complications may appear that affect various organs, e.g. hepatic or renal impairment and retarded growth.
The clinical expression of the disease and its evolution are highly variable among individuals.
Painful vaso-occlusive crises are the most common cause of hospitalisation in sickle cell anaemia patients, and therefore represent a very high cost for society.
Hydroxyurea is currently recognised as the reference drug treatment for this disease.
Approximately 100,000 persons suffer from sickle cell anaemia in the USA compared with approximately 60,000 in Europe. In both cases, it is considered to be a rare disease (less than 5 cases per 10,000 inhabitants)
About ADDMEDICA
Founded in 2005, ADDMEDICA is a pharmaceutical company based in France, focused on developing and marketing medical products for rare diseases and unmet medical needs. ADDMEDICA’s main therapeutic and development fields are
• Genetic diseases and their treatment,
• Organ transplant and tissue replacement,
• Wound healing and tissue regeneration.
ADDMEDICA developed Siklos® specifically for sickle cell anaemia. In 2007, ADDMEDICA obtained a marketing authorisation in Europe for Siklos® , the first and sole medicinal product indicated in the prevention of recurrent painful vaso-occlusive crises in sickle cell anaemia. ADDMEDICA now has FDA-approval for Silos® in the treatment of sickle cell disease in paediatric patients 2 years of age and older. Based on its expertise in the field, ADDMEDICA is pursuing the international development of Siklos® .
For more information: http://www.addmedica.com
About Medunik USA
Based in Pennsylvania, Medunik USA works to improve the health and quality of life of Americans living with rare diseases by making several orphan drug therapies available in the United States. With strategic partnerships worldwide, the company has critical experience in approval and market access processes as well as the marketing of orphan drug therapies. For more information: www.medunikusa.com .
Sources:
Concerning the disease
https://www.nhlbi.nih.gov/health/health-topics/topics/sca
https://www.orpha.net/data/patho/Pub/fr/Drepanocytose-FRfrPub125v01.pdf
Concerning Siklos® in the USA
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf
Concerning Siklos® in Europe
Concerning Escort-HU
https://clinicaltrials.gov/ct2/show/NCT02516579
View source version on businesswire.com: http://www.businesswire.com/news/home/20180315005138/en/
Contact:
Yucatan
Caroline Prince
cprince@yucatan.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Reports a Record AED 14.6 Billion in Revenue for the First Half of 2025 and Approves Dividend Payment of AED 3.1 Billion8.8.2025 17:47:00 CEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808832927/en/ Dubai Electricity and Water Authority PJSC reports a record AED 14.6 billion in revenue for the first half of 2025 and approves dividend payment of AED 3.1 billion (Graphic: AETOSWire) “DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highn
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills8.8.2025 15:54:00 CEST | Press release
Sutherland, a global leader in business and digital transformation, has partnered with the Philippine Government to launch a dedicated AI Academy. This strategic initiative supports the Philippine government’s broader efforts to empower the Filipino workforce for an AI-driven future. The AI Academy will offer practical, industry-aligned training designed to equip Filipino professionals with skills to integrate artificial intelligence into their work. It aims to strengthen the country’s talent pool by developing capabilities that are increasingly in demand across sectors, whether as AI specialists, prompt engineers, or cybersecurity professionals. The program will prepare participants to harness AI in driving productivity, advancing innovation, and pursuing high-value opportunities across industries. “This initiative is a vital step toward our goal of building a digitally resilient and inclusive workforce, said President Ferdinand R. Marcos Jr. “By expanding access to training in future
Baraja Appoints IP Pioneer to Lead Global Sale of Spectrum-Scan™ LiDAR IP Assets8.8.2025 15:00:00 CEST | Press release
IP Pioneer appointed to lead competitive acquisition process Baraja Pty Ltd (“Baraja”), the Australian pioneer behind the revolutionary Spectrum‑Scan™ LiDAR architecture, has announced a global initiative to commercialize its full suite of patented LiDAR intellectual property and technical assets. The company has appointed IP Pioneer Group Incas the exclusive worldwide advisor to manage this competitive transaction process. Baraja redefined LiDAR performance through its Spectrum-Scan™ technology—a transformative solid-state architecture that steers the laser beam by tuning its wavelength through a dispersive prism or grating, eliminating moving parts. This breakthrough enables long-range, high-resolution 3D sensing that is inherently immune to alignment drift, sunlight, and multi-LiDAR interference. Having achieved significant technical milestones in LiDAR innovation, Baraja is now strategically evolving its business focus to pursue new frontiers in sensing and perception. This initiat
Andersen Consulting annoncerer samarbejdsaftale med Virtual, Inc.8.8.2025 14:48:00 CEST | Pressemeddelelse
Andersen Consulting offentliggør en samarbejdsaftale med Virtual, Inc., et amerikansk firma, der er kendt for sin dybe ekspertise inden for strategi og drift for teknologikonsortier, standardudviklingsorganisationer og andre medlemsdrevne grupper. Virtual, Inc. er kendt for sin praktiske tilgang og resultatorienterede arbejdsmetode og har dokumenteret efaring inden for støtte til missionsdrevne, samarbejdsbaserede organisationer. Med en boutiquevirksomheds smidighed og en global aktørs kapaciteter hjælper Virtual førende teknologivirksomheder og standardiseringsorganer med at fremskynde innovation, opnå enighed og øge indflydelsen på tværs af det digitale økosystem. Siden grundlæggelsen i 1999 har Virtual leveret skræddersyet strategisk rådgivning og driftsmæssig support til kunder over hele verden – navnlig inden for teknologisektoren – med tjenester, der spænder over governance, medlemskabs- og certificeringsadministration, support til udvikling af standarder, eventmanagement, market
Andersen Consulting tilføjer samarbejdspartneren 460degrees8.8.2025 14:39:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin strategi og sine teknologiske transformationsevner med tilføjelsen af samarbejdspartneren 460degrees, hvilket yderligere styrker organisationens mulighed for at hjælpe kunder med at skabe innovation, transformation og forretningsresultater på stadig mere komplekse markeder. 460degrees blev stiftet i 2004 og leverer specialiserede tjenester inden for projektlevering, strategisk datastyring, transformationsrådgivning, cybersikkerhed og digital tillid. Virksomheden leverer konsulentløsninger til kunder i en række brancher, herunder offentlig forvaltning, detailhandel og finans, og hjælper dem med at navigere i kompleksiteten og opnå hurtigere resultater. Med særlig vægt på eksekvering og levering arbejder 460degrees på kundesiden for at guide organisationer gennem hele indkøbsprocessen og sikre, at de har adgang til den rette ekspertise og de rette nøglepersoner i alle faser af deres digitale transformation. "Samarbejdet med Andersen Consulting giver os mul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom